OM2 Stock Overview
Operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Orthofix Medical Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$15.80 |
| 52 Week High | US$16.30 |
| 52 Week Low | US$8.90 |
| Beta | 1.05 |
| 11 Month Change | 16.18% |
| 3 Month Change | 22.48% |
| 1 Year Change | 41.07% |
| 33 Year Change | -48.03% |
| 5 Year Change | -60.10% |
| Change since IPO | -15.96% |
Recent News & Updates
Recent updates
Shareholder Returns
| OM2 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 9.0% | -3.6% | -2.2% |
| 1Y | 41.1% | -3.5% | 13.3% |
Return vs Industry: OM2 exceeded the German Medical Equipment industry which returned -2.7% over the past year.
Return vs Market: OM2 exceeded the German Market which returned 13.6% over the past year.
Price Volatility
| OM2 volatility | |
|---|---|
| OM2 Average Weekly Movement | 9.4% |
| Medical Equipment Industry Average Movement | 5.3% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: OM2's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: OM2's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1980 | 1,634 | Massimo Calafiore | www.orthofix.com |
Orthofix Medical Inc. operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions.
Orthofix Medical Inc. Fundamentals Summary
| OM2 fundamental statistics | |
|---|---|
| Market cap | €595.26m |
| Earnings (TTM) | -€110.78m |
| Revenue (TTM) | €709.45m |
0.9x
P/S Ratio-5.5x
P/E RatioIs OM2 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OM2 income statement (TTM) | |
|---|---|
| Revenue | US$771.65m |
| Cost of Revenue | US$226.21m |
| Gross Profit | US$545.44m |
| Other Expenses | US$665.93m |
| Earnings | -US$120.49m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 07, 2024
| Earnings per share (EPS) | -3.16 |
| Gross Margin | 70.68% |
| Net Profit Margin | -15.62% |
| Debt/Equity Ratio | 21.6% |
How did OM2 perform over the long term?
See historical performance and comparison